Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Natural Killer (NK) Cell Therapeutics Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Natural Killer (NK) Cell Therapeutics Industry
  • 1.7 COVID-19 Impact: Natural Killer (NK) Cell Therapeutics Market Trends

    • 2 Global Natural Killer (NK) Cell Therapeutics Quarterly Market Size Analysis

    • 2.1 Natural Killer (NK) Cell Therapeutics Business Impact Assessment - COVID-19
      • 2.1.1 Global Natural Killer (NK) Cell Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Natural Killer (NK) Cell Therapeutics Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Natural Killer (NK) Cell Therapeutics Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Natural Killer (NK) Cell Therapeutics Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Natural Killer (NK) Cell Therapeutics Market
    • 3.4 Key Players Natural Killer (NK) Cell Therapeutics Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Natural Killer (NK) Cell Therapeutics Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Mogamulizumab
      • 1.4.2 Lorvotuzumab Mertansine
      • 1.4.3 Others
    • 4.2 By Type, Global Natural Killer (NK) Cell Therapeutics Market Size, 2019-2021

    5 Impact of Covid-19 on Natural Killer (NK) Cell Therapeutics Segments, By Application

    • 5.1 Overview
      • 5.5.1 Cancer
      • 5.5.2 Cardiovascular Diseases
      • 5.5.3 Others
    • 5.2 By Application, Global Natural Killer (NK) Cell Therapeutics Market Size, 2019-2021
      • 5.2.1 By Application, Global Natural Killer (NK) Cell Therapeutics Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Chipscreen Biosciences (China)
      • 7.1.1 Chipscreen Biosciences (China) Business Overview
      • 7.1.2 Chipscreen Biosciences (China) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.1.3 Chipscreen Biosciences (China) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.1.4 Chipscreen Biosciences (China) Response to COVID-19 and Related Developments
    • 7.2 Affimed NV (Netherlands)
      • 7.2.1 Affimed NV (Netherlands) Business Overview
      • 7.2.2 Affimed NV (Netherlands) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.2.3 Affimed NV (Netherlands) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.2.4 Affimed NV (Netherlands) Response to COVID-19 and Related Developments
    • 7.3 Altor BioScience Corporation (USA)
      • 7.3.1 Altor BioScience Corporation (USA) Business Overview
      • 7.3.2 Altor BioScience Corporation (USA) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.3.3 Altor BioScience Corporation (USA) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.3.4 Altor BioScience Corporation (USA) Response to COVID-19 and Related Developments
    • 7.4 Innate Pharma SA (France)
      • 7.4.1 Innate Pharma SA (France) Business Overview
      • 7.4.2 Innate Pharma SA (France) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.4.3 Innate Pharma SA (France) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.4.4 Innate Pharma SA (France) Response to COVID-19 and Related Developments
    • 7.5 Takeda Pharmaceutical (Japan)
      • 7.5.1 Takeda Pharmaceutical (Japan) Business Overview
      • 7.5.2 Takeda Pharmaceutical (Japan) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.5.3 Takeda Pharmaceutical (Japan) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.5.4 Takeda Pharmaceutical (Japan) Response to COVID-19 and Related Developments
    • 7.6 Sorrento Therapeutics Inc. (USA)
      • 7.6.1 Sorrento Therapeutics Inc. (USA) Business Overview
      • 7.6.2 Sorrento Therapeutics Inc. (USA) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.6.3 Sorrento Therapeutics Inc. (USA) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.6.4 Sorrento Therapeutics Inc. (USA) Response to COVID-19 and Related Developments
    • 7.7 NantKwest Inc. (USA)
      • 7.7.1 NantKwest Inc. (USA) Business Overview
      • 7.7.2 NantKwest Inc. (USA) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.7.3 NantKwest Inc. (USA) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.7.4 NantKwest Inc. (USA) Response to COVID-19 and Related Developments
    • 7.8 Bristol-Myers Squibb (USA)
      • 7.8.1 Bristol-Myers Squibb (USA) Business Overview
      • 7.8.2 Bristol-Myers Squibb (USA) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.8.3 Bristol-Myers Squibb (USA) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.8.4 Bristol-Myers Squibb (USA) Response to COVID-19 and Related Developments
    • 7.9 NKT Therapeutics (USA)
      • 7.9.1 NKT Therapeutics (USA) Business Overview
      • 7.9.2 NKT Therapeutics (USA) Natural Killer (NK) Cell Therapeutics Quarterly Revenue, 2020
      • 7.9.3 NKT Therapeutics (USA) Natural Killer (NK) Cell Therapeutics Product Introduction
      • 7.9.4 NKT Therapeutics (USA) Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Natural Killer (NK) Cell Therapeutics, including the following market information:
      Global Natural Killer (NK) Cell Therapeutics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Natural Killer (NK) Cell Therapeutics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Natural Killer (NK) Cell Therapeutics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Natural Killer (NK) Cell Therapeutics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Chipscreen Biosciences (China), Affimed NV (Netherlands), Altor BioScience Corporation (USA), Innate Pharma SA (France), Takeda Pharmaceutical (Japan), Sorrento Therapeutics Inc. (USA), NantKwest Inc. (USA), Bristol-Myers Squibb (USA), NKT Therapeutics (USA), etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Mogamulizumab
      Lorvotuzumab Mertansine
      Others

      Based on the Application:
      Cancer
      Cardiovascular Diseases
      Others

      Buy now